New Drug-Eluting Stent Employs Technology from DSM Biomedical

Trade show 101. Lesson one: It helps when you’ve got big news to highlight your company’s participation in an event.

The folks at Berkeley, Calif.-based DSM Biomedical can check that one off their list.

A few days prior to its participation at Compamed 2011, the international medical products trade fair held in Dusseldorf, Germany, DSM—a provider of biomedical materials—scored an important piece of new business. The company reported that its proprietary ComfortCoat hydrophilic coating would be used on the delivery system of the new Cre8 drug-eluting stent (DES) from Carbostent & Implantable Devices (CID) SpA. The stent received CE Mark earlier this year.

Saluggia, Italy-based CID chose ComfortCoat for its stent technology, because, according to CID officials, it “facilitates the treatment of more complex patient anatomies by enhancing the deliverability of its stent during percutaneous coronary intervention procedures.”

Franco Vallana, president and CEO of CID SpA, said: “The launch of Cre8 DES aligns with our mission of supporting interventional cardiologists and their patients with the development of innovative systems that positively impact patient outcomes, in terms of efficacy and safety, while also helping to reduce costs within the healthcare delivery system. By collaborating with DSM, we are able to ensure interventional cardiologists receive the benefits of the world’s most advanced technologies within our drug eluting stent systems.”

John Marugg, the coatings business manager for DSM Biomedical said the partnership continues his firm’s “commitment to providing innovative material solutions for the cardiovascular market, which, ultimately, help to lower patient risk and improve procedural outcomes.”

DSM specializes in biomedical materials, coatings, drug delivery and other contract manufacturing, such as custom tubing and contract research and development.

During the recent Transcatheter Cardiovascular Therapeutics annual meeting held earlier in November in San Francisco, Calif., the Cre8 stent held up well in clinical trial data presented pitting it against the Taxus Liberté from Boston Scientific.

The Cre8 stent uses reservoirs on the surface of the stent instead of polymer to hold the sirolimus drug.

In the NEXT study that used that stent, late lumen loss as a surrogate endpoint for restenosis was lower with the novel stent than with the durable polymer paclitaxel-eluting Taxus Liberté stent (0.14 versus 0.34 mm at six months which met superiority criteria at P<0.0001) among 323 non-acute randomized patients.

Other six-month clinical outcomes, including stent thrombosis, were equal between the two.